Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.51 |
| ▸ | CNR1 | P21554 | 11/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171309 | 0.91 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL775376 | 0.89 | CNR2 (0.58) | CNR2CNR1MAPK14 | |
| SCHEMBL10219883 | 0.88 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL14693080 | 0.85 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL13413894 | 0.84 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL12746886 | 0.81 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL10171319 | 0.81 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL12746885 | 0.80 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL10171346 | 0.80 | CNR2 (0.60) | CNR2CNR1MAPK14 | |
| SCHEMBL1691454 | 0.80 | CNR2 (0.58) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362039-B2 | Therapeutic uses of compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885MAPK14 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.